Quick Facts
| Peptide name | Thymosin Alpha-1 |
|---|---|
| Research category | Immunity |
| Molecular formula | C₁₂₉H₂₁₅N₃₃O₅₅ |
| Molecular weight | ≈ 3108 g/mol |
| Sequence | 28-residue acetylated peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN) |
| Primary research interest | T-cell maturation, dendritic-cell function, and Toll-like-receptor immune signaling |
| Storage considerations | Lyophilized powder stored frozen at −20 °C, kept dry and dark; reconstituted solution refrigerated at 2–8 °C and protected from light. |
| Solubility notes | Highly water-soluble owing to its abundant charged residues; readily dissolves in sterile or bacteriostatic water. |
| Related compounds | Thymulin, Thymalin, LL-37, KPV |
Introduction
Research Use Only
Thymosin Alpha-1 is discussed here strictly as an investigational research compound for educational and laboratory reference. It is not guidance for human use, diagnosis, treatment, or prevention of disease.
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide derived from the precursor protein prothymosin alpha and originally isolated from thymic tissue. It is the most extensively studied of the thymic immunomodulatory peptides, and within this library it is the natural companion to Thymulin, the zinc-dependent thymic nonapeptide. Thymosin Alpha-1 is examined in research for its broad capacity to modulate immune responses — restoring balance rather than simply amplifying or suppressing immunity.
The conceptual interest in Thymosin Alpha-1 lies in its action at the interface of innate and adaptive immunity. It is studied for effects on T-lymphocytes and dendritic cells while also engaging pattern-recognition receptors of the innate system. This dual reach is why it appears across diverse research contexts, from antiviral immunity to immune support in study populations with compromised immune function.
This profile covers what Thymosin Alpha-1 is, its molecular characteristics, its receptor-level mechanisms, the immune research it appears in, and how it compares with related thymic and host-defense peptides such as Thymulin and LL-37. Related entries are catalogued in the peptide database.
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a 28-residue acetylated peptide corresponding to the N-terminal region of prothymosin alpha. It was among the first biologically active fractions identified in thymosin fraction 5, an early thymic extract, and was subsequently characterized as the component most associated with immune-modulating activity. The mature peptide is typically N-terminally acetylated, a modification relevant to its stability and recognition.
A synthetic version of Thymosin Alpha-1 has been developed and studied internationally in immunology research, including as an adjunct in contexts of infection and immune dysfunction. Because it is a defined, reproducible sequence rather than a crude extract, it is far better characterized than many thymic preparations, which is part of why it has the deepest research base in this peptide family.
At a glance
Class: 28-residue thymic immunomodulatory peptide (from prothymosin alpha). Key features: N-terminal acetylation; highly water-soluble. Research focus: T-cell maturation, dendritic-cell activation, and Toll-like-receptor signaling.
Molecular and structural characteristics
Thymosin Alpha-1 is notable for its highly acidic, charged composition — it is rich in glutamate, aspartate, and lysine residues, giving it strong water solubility and a largely disordered conformation in solution. Like its parent prothymosin alpha, it behaves as an intrinsically disordered peptide, adopting more defined structure upon interacting with partners or membranes rather than maintaining a fixed fold on its own.
The N-terminal acetyl group is a defining structural detail, protecting the terminus and influencing how the peptide is recognized. The combination of small size, disorder, and abundant charge makes Thymosin Alpha-1 unusually soluble and easy to handle relative to more hydrophobic peptides, while its biological specificity arises from its sequence and interaction partners.
| Property | Value / description |
|---|---|
| Peptide class | Thymic immunomodulatory peptide |
| Origin | N-terminal fragment of prothymosin alpha |
| Length | 28 amino acids |
| Modification | N-terminal acetylation |
| Conformation | Largely disordered in solution |
| Molecular weight | ≈ 3108 g/mol |
Mechanism of action
Thymosin Alpha-1 is studied as a pleiotropic immunomodulator, meaning it acts on several arms of the immune system rather than through a single dedicated receptor. A central thread is its association with the maturation and differentiation of T-lymphocytes, helping precursor cells acquire functional competence — consistent with its thymic origin and the thymus's role as the site of T-cell education.
At the innate level, Thymosin Alpha-1 is studied as a modulator of Toll-like receptors (TLRs), particularly TLR2 and TLR9, on dendritic cells and monocytes. Through this pathway it is associated with enhanced dendritic-cell activation and antigen presentation, linking innate sensing to the priming of adaptive responses. Researchers also report effects on cytokine balance and on natural-killer-cell activity, again pointing to a regulatory, balancing role.
Because it engages both innate and adaptive components, Thymosin Alpha-1 is studied as a tool to recalibrate dysregulated immunity in either direction — supporting responses that are too weak and restraining those that are excessive. This contrasts with the narrower, zinc-dependent action of Thymulin and with direct antimicrobial host-defense peptides such as LL-37 and KPV.
- Associated with T-lymphocyte maturation and differentiation.
- Linked to dendritic-cell activation and antigen presentation.
- Studied as a modulator of Toll-like receptors (TLR2/TLR9).
- Reported effects on cytokine balance and NK-cell activity.
Immune modulation research
Thymosin Alpha-1 has one of the broadest research footprints of any thymic peptide. It has been studied as an immune adjunct in contexts of viral infection, where investigators examined its association with enhanced antiviral immune responses, and in study populations with immune suppression, where its capacity to support T-cell and dendritic-cell function is the central rationale. It has also been examined as an adjuvant alongside vaccines in research settings.
A recurring theme is that Thymosin Alpha-1 is framed as a restorative modulator rather than a blunt stimulant: across diverse models it is associated with steering immune signaling toward balance. This immunoregulatory framing connects it to wider research on inflammation and host defense, including peptides such as KPV, studied for anti-inflammatory effects, and LL-37, studied at the innate-immunity frontier.
Evidence caveat
Thymosin Alpha-1 has a larger clinical research base than most thymic peptides, but findings vary by indication, population, and study quality. Results are described here as research observations, not as outcomes for any individual.
Comparison: Thymosin Alpha-1 vs Thymulin vs LL-37
Thymosin Alpha-1 is most often compared with Thymulin, the zinc-dependent thymic nonapeptide, and contrasted with LL-37, a host-defense peptide acting at the innate-immunity level. All three appear in immunity research but differ in size, mechanism, and emphasis.
| Compound | Type | Primary mechanism studied | Note |
|---|---|---|---|
| Thymosin Alpha-1 | 28-residue thymic peptide | T-cell maturation; TLR/dendritic-cell modulation | Broadest research base of the thymic peptides |
| Thymulin | Zinc-dependent nonapeptide | T-cell differentiation (zinc-dependent) | Activity tied to zinc status (FTS-Zn) |
| LL-37 | Cathelicidin host-defense peptide | Direct antimicrobial + innate signaling | Innate-immunity emphasis, not thymic |
Researchers studying thymic immunomodulation frequently examine Thymosin Alpha-1 alongside Thymulin, while those focused on innate defense look to LL-37. Full entries for each are in the peptide database.
Half-life and pharmacokinetic considerations
Thymosin Alpha-1 has a relatively short circulating half-life, generally reported on the order of a couple of hours, reflecting peptidase activity acting on a small, soluble peptide. This is longer than the minutes-scale clearance of very short peptides like Thymulin, but still short compared with albumin-binding or otherwise stabilized peptides.
Because its effects are studied as immunomodulatory rather than tied to sustained receptor occupancy, research interest often centers on the downstream immune changes that persist after the peptide itself is cleared. As with other peptides, schedule and exposure are treated as experimental variables in the studies that examine it.
Reconstitution and handling considerations
Lyophilized Thymosin Alpha-1 is reconstituted with sterile or bacteriostatic water. Its abundant charged residues make it highly water-soluble, so it dissolves readily, but the diluent should still be added slowly down the vial wall and the vial swirled gently rather than shaken. The reconstituted solution should be clear and colorless; cloudiness or particulates indicate it should be discarded.
Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.
- Add diluent slowly; swirl gently rather than shaking.
- Confirm the solution is clear and colorless before use.
- Protect from light and excess warmth.
- Aliquot reconstituted material to avoid repeated freeze–thaw cycles.
Storage considerations
Lyophilized Thymosin Alpha-1 is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting before freezing reduces how often a given solution is cycled.
| Form | Condition | Notes |
|---|---|---|
| Lyophilized powder | −20 °C, dark, dry | Most stable for long-term holding |
| Reconstituted solution | 2–8 °C, protected from light | Use within a limited window |
| Freeze–thaw | Avoid repeated cycles | Aliquot to minimize cycling |
Research limitations
Although Thymosin Alpha-1 has a deeper research base than most thymic peptides, that evidence spans many indications of varying study quality, and its pleiotropic, multi-target action makes mechanisms harder to isolate than for a single-receptor agonist. Reported effects depend on the immune context, population, and study design. It is described here strictly for research reference.
- Pleiotropic action makes single-mechanism attribution difficult.
- Evidence spans many indications of variable study quality.
- Reported effects are context-, population-, and design-dependent.
- It is not described here as a therapy, only as a research compound.
Research Use Only
This profile is for educational and laboratory reference. Thymosin Alpha-1 is not intended for human consumption, diagnosis, treatment, or prevention of disease.
Frequently Asked Questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a 28-amino-acid thymic peptide derived from prothymosin alpha. It is the most studied thymic immunomodulatory peptide, examined in research for its association with T-cell maturation, dendritic-cell activation, and Toll-like-receptor signaling.
How does Thymosin Alpha-1 work?
It acts as a pleiotropic immunomodulator. Research associates it with T-lymphocyte maturation, dendritic-cell activation, modulation of Toll-like receptors (notably TLR2 and TLR9), and effects on cytokine balance and natural-killer-cell activity, bridging innate and adaptive immunity.
How is Thymosin Alpha-1 different from Thymulin?
Both are thymic immunomodulatory peptides, but Thymosin Alpha-1 is a 28-residue peptide with broad innate and adaptive effects, while Thymulin is a short nonapeptide whose activity strictly depends on bound zinc. Thymosin Alpha-1 also has a larger research base.
Is Thymosin Alpha-1 a stimulant or a suppressant of immunity?
Research frames it as a modulator rather than a one-directional agent. It is studied for its capacity to recalibrate dysregulated immune responses — supporting weak responses and restraining excessive ones — depending on the context.
What is the half-life of Thymosin Alpha-1?
Reports generally place its circulating half-life on the order of a couple of hours, reflecting peptidase activity on a small soluble peptide. Research interest often centers on downstream immune changes that persist after the peptide is cleared.
Related Research Profiles
Thymulin
Thymulin is a zinc-dependent thymic nonapeptide studied in immunological and neuroendocrine research for its association with T-cell differentiation, immune homeostasis, and anti-inflammatory signaling.
Read profileLL-37
LL-37 is the only human cathelicidin antimicrobial peptide, studied in preclinical research for its association with broad host-defense activity, immune modulation, and wound-related signaling.
Read profileKPV
KPV is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) studied in preclinical models for its association with anti-inflammatory and immunomodulatory signaling, particularly in mucosal and skin tissue.
Read profileReferences
- Garaci E, et al. Thymosin alpha 1: from bench to bedside. Ann N Y Acad Sci. 2007.Source
- Romani L, et al. Thymosin alpha1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. Blood. 2004.
- King R, Tuthill C. Immune modulation with thymosin alpha 1 treatment. Vitam Horm. 2016.Source
Research Use Only
For research use only. Not intended for human consumption, diagnosis, treatment, or prevention of disease. The information on this page is provided for educational and laboratory reference purposes only.